SOLTA MEDICAL INC 4
4 · SOLTA MEDICAL INC · Filed Jan 27, 2014
Insider Transaction Report
Form 4
Nardoci Jeffrey C
Vice President of Marketing
Transactions
- Exercise/Conversion
Common Stock
2014-01-23+14,906→ 14,906 total - Disposition from Tender
Common Stock
2014-01-23$2.92/sh−130,580$381,294→ 0 total - Disposition from Tender
Common Stock
2014-01-23$2.92/sh−14,906$43,526→ 0 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2014-01-23$0.44/sh−68,750$30,250→ 0 totalExercise: $2.48Exp: 2019-10-28→ Common Stock (68,750 underlying) - Disposition from Tender
Common Stock
2014-01-23$2.92/sh−8,346$24,370→ 0 total - Exercise/Conversion
Performance Restricted Stock Unit
2014-01-23−8,346→ 0 totalExp: 2022-02-08→ Common Stock (8,346 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2014-01-23$1.01/sh−52,085$52,606→ 0 totalExercise: $1.91Exp: 2020-02-08→ Common Stock (52,085 underlying) - Exercise/Conversion
Common Stock
2014-01-23+8,346→ 8,346 total - Exercise/Conversion
Performance Restricted Stock Unit
2014-01-23−14,906→ 0 totalExp: 2023-02-04→ Common Stock (14,906 underlying)
Footnotes (3)
- [F1]Includes 107,133 shares deemed acquired pursuant to the grant of restricted stock units ("RSU's" ) on various dates. The vesting of the RSU's was accelerated in connection with the merger of the Issuer with Valeant Pharmaceuticals International, a Delaware corporation (the "Merger").
- [F2]Each performance right represented a contingent right to receive a share of Issuer common stock based on the Issuer's stock price performance. In connection with the Merger, the vesting (thus, the settlement) of the performance right was accelerated.
- [F3]This option, which had become fully vested and exercisable, was cancelled at the closing of the Merger in exchange for a cash payment equal to the product of (a) the number of shares underlying this option and (b) the difference between the merger consideration of $2.92 per share and the exercise price per share of this option.